2024-01-012024-12-312024-12-31false127494686 DEGREES BIOSCIENCE UK LTD2025-03-1810320falseiso4217:GBPxbrli:pure127494682024-01-01127494682024-12-31127494682024-01-012024-12-31127494682023-01-01127494682023-12-31127494682023-01-012023-12-3112749468bus:SmallEntities2024-01-012024-12-3112749468bus:AuditExempt-NoAccountantsReport2024-01-012024-12-3112749468bus:FullAccounts2024-01-012024-12-3112749468bus:PrivateLimitedCompanyLtd2024-01-012024-12-3112749468core:WithinOneYear2024-12-3112749468core:AfterOneYear2024-12-3112749468core:WithinOneYear2023-12-3112749468core:AfterOneYear2023-12-3112749468core:ShareCapital2024-12-3112749468core:SharePremium2024-12-3112749468core:RevaluationReserve2024-12-3112749468core:OtherReservesSubtotal2024-12-3112749468core:RetainedEarningsAccumulatedLosses2024-12-3112749468core:ShareCapital2023-12-3112749468core:SharePremium2023-12-3112749468core:RevaluationReserve2023-12-3112749468core:OtherReservesSubtotal2023-12-3112749468core:RetainedEarningsAccumulatedLosses2023-12-3112749468core:LandBuildings2024-12-3112749468core:PlantMachinery2024-12-3112749468core:Vehicles2024-12-3112749468core:FurnitureFittings2024-12-3112749468core:OfficeEquipment2024-12-3112749468core:NetGoodwill2024-12-3112749468core:IntangibleAssetsOtherThanGoodwill2024-12-3112749468core:ListedExchangeTraded2024-12-3112749468core:UnlistedNon-exchangeTraded2024-12-3112749468core:LandBuildings2023-12-3112749468core:PlantMachinery2023-12-3112749468core:Vehicles2023-12-3112749468core:FurnitureFittings2023-12-3112749468core:OfficeEquipment2023-12-3112749468core:NetGoodwill2023-12-3112749468core:IntangibleAssetsOtherThanGoodwill2023-12-3112749468core:ListedExchangeTraded2023-12-3112749468core:UnlistedNon-exchangeTraded2023-12-3112749468core:LandBuildings2024-01-012024-12-3112749468core:PlantMachinery2024-01-012024-12-3112749468core:Vehicles2024-01-012024-12-3112749468core:FurnitureFittings2024-01-012024-12-3112749468core:OfficeEquipment2024-01-012024-12-3112749468core:NetGoodwill2024-01-012024-12-3112749468core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3112749468core:ListedExchangeTraded2024-01-012024-12-3112749468core:UnlistedNon-exchangeTraded2024-01-012024-12-3112749468core:MoreThanFiveYears2024-01-012024-12-3112749468core:Non-currentFinancialInstruments2024-12-3112749468core:Non-currentFinancialInstruments2023-12-3112749468dpl:CostSales2024-01-012024-12-3112749468dpl:DistributionCosts2024-01-012024-12-3112749468core:LandBuildings2024-01-012024-12-3112749468core:PlantMachinery2024-01-012024-12-3112749468core:Vehicles2024-01-012024-12-3112749468core:FurnitureFittings2024-01-012024-12-3112749468core:OfficeEquipment2024-01-012024-12-3112749468dpl:AdministrativeExpenses2024-01-012024-12-3112749468core:NetGoodwill2024-01-012024-12-3112749468core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3112749468dpl:GroupUndertakings2024-01-012024-12-3112749468dpl:ParticipatingInterests2024-01-012024-12-3112749468dpl:GroupUndertakingscore:ListedExchangeTraded2024-01-012024-12-3112749468core:ListedExchangeTraded2024-01-012024-12-3112749468dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-01-012024-12-3112749468core:UnlistedNon-exchangeTraded2024-01-012024-12-3112749468dpl:CostSales2023-01-012023-12-3112749468dpl:DistributionCosts2023-01-012023-12-3112749468core:LandBuildings2023-01-012023-12-3112749468core:PlantMachinery2023-01-012023-12-3112749468core:Vehicles2023-01-012023-12-3112749468core:FurnitureFittings2023-01-012023-12-3112749468core:OfficeEquipment2023-01-012023-12-3112749468dpl:AdministrativeExpenses2023-01-012023-12-3112749468core:NetGoodwill2023-01-012023-12-3112749468core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3112749468dpl:GroupUndertakings2023-01-012023-12-3112749468dpl:ParticipatingInterests2023-01-012023-12-3112749468dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-012023-12-3112749468core:ListedExchangeTraded2023-01-012023-12-3112749468dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-012023-12-3112749468core:UnlistedNon-exchangeTraded2023-01-012023-12-3112749468core:NetGoodwill2024-12-3112749468core:IntangibleAssetsOtherThanGoodwill2024-12-3112749468core:LandBuildings2024-12-3112749468core:PlantMachinery2024-12-3112749468core:Vehicles2024-12-3112749468core:FurnitureFittings2024-12-3112749468core:OfficeEquipment2024-12-3112749468core:AfterOneYear2024-12-3112749468core:WithinOneYear2024-12-3112749468core:ListedExchangeTraded2024-12-3112749468core:UnlistedNon-exchangeTraded2024-12-3112749468core:ShareCapital2024-12-3112749468core:SharePremium2024-12-3112749468core:RevaluationReserve2024-12-3112749468core:OtherReservesSubtotal2024-12-3112749468core:RetainedEarningsAccumulatedLosses2024-12-3112749468core:NetGoodwill2023-12-3112749468core:IntangibleAssetsOtherThanGoodwill2023-12-3112749468core:LandBuildings2023-12-3112749468core:PlantMachinery2023-12-3112749468core:Vehicles2023-12-3112749468core:FurnitureFittings2023-12-3112749468core:OfficeEquipment2023-12-3112749468core:AfterOneYear2023-12-3112749468core:WithinOneYear2023-12-3112749468core:ListedExchangeTraded2023-12-3112749468core:UnlistedNon-exchangeTraded2023-12-3112749468core:ShareCapital2023-12-3112749468core:SharePremium2023-12-3112749468core:RevaluationReserve2023-12-3112749468core:OtherReservesSubtotal2023-12-3112749468core:RetainedEarningsAccumulatedLosses2023-12-3112749468core:NetGoodwill2023-01-0112749468core:IntangibleAssetsOtherThanGoodwill2023-01-0112749468core:LandBuildings2023-01-0112749468core:PlantMachinery2023-01-0112749468core:Vehicles2023-01-0112749468core:FurnitureFittings2023-01-0112749468core:OfficeEquipment2023-01-0112749468core:AfterOneYear2023-01-0112749468core:WithinOneYear2023-01-0112749468core:ListedExchangeTraded2023-01-0112749468core:UnlistedNon-exchangeTraded2023-01-0112749468core:ShareCapital2023-01-0112749468core:SharePremium2023-01-0112749468core:RevaluationReserve2023-01-0112749468core:OtherReservesSubtotal2023-01-0112749468core:RetainedEarningsAccumulatedLosses2023-01-0112749468core:AfterOneYear2024-01-012024-12-3112749468core:WithinOneYear2024-01-012024-12-3112749468core:Non-currentFinancialInstrumentscore:CostValuation2024-01-012024-12-3112749468core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-01-012024-12-3112749468core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-01-012024-12-3112749468core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-01-012024-12-3112749468core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-01-012024-12-3112749468core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-01-012024-12-3112749468core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-01-012024-12-3112749468core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-01-012024-12-3112749468core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-01-012024-12-3112749468core:Non-currentFinancialInstrumentscore:CostValuation2024-12-3112749468core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-12-3112749468core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-12-3112749468core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-12-3112749468core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-12-3112749468core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-12-3112749468core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-12-3112749468core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-12-3112749468core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-12-3112749468core:Non-currentFinancialInstrumentscore:CostValuation2023-12-3112749468core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-12-3112749468core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-12-3112749468core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-12-3112749468core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-12-3112749468core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-12-3112749468core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-12-3112749468core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-12-3112749468core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-12-3112749468bus:Director12024-01-012024-12-3112749468core:FurnitureFittingsToolsEquipment2023-12-3112749468core:FurnitureFittingsToolsEquipment2024-01-012024-12-3112749468core:FurnitureFittingsToolsEquipment2024-12-31

6 DEGREES BIOSCIENCE UK LTD

Registered Number
12749468
(England and Wales)

Unaudited Financial Statements for the Year ended
31 December 2024

6 DEGREES BIOSCIENCE UK LTD
Company Information
for the year from 1 January 2024 to 31 December 2024

Director

Trent Gordon Scanlen

Registered Address

Unit 12 Mill Farm Business Park
Millfield Road
Hounslow
TW4 5PY

Registered Number

12749468 (England and Wales)
6 DEGREES BIOSCIENCE UK LTD
Balance Sheet as at
31 December 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Intangible assets3446506
Tangible assets491,066103,488
91,512103,994
Current assets
Stocks5188,213149,368
Debtors1,543,1251,265,792
Cash at bank and on hand4,7994,064
1,736,1371,419,224
Creditors amounts falling due within one year6(198,207)(82,478)
Net current assets (liabilities)1,537,9301,336,746
Total assets less current liabilities1,629,4421,440,740
Net assets1,629,4421,440,740
Capital and reserves
Called up share capital11
Profit and loss account1,629,4411,440,739
Shareholders' funds1,629,4421,440,740
The financial statements were approved and authorised for issue by the Director on 18 March 2025, and are signed on its behalf by:
Trent Gordon Scanlen
Director
Registered Company No. 12749468
6 DEGREES BIOSCIENCE UK LTD
Notes to the Financial Statements
for the year ended 31 December 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Intangible assets
Intangible fixed assets (including purchased goodwill and patents) are included at cost less accumulated amortisation.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
2.Average number of employees

20242023
Average number of employees during the year22
3.Intangible assets

Other

Total

££
Cost or valuation
At 01 January 24600600
At 31 December 24600600
Amortisation and impairment
At 01 January 249494
Charge for year6060
At 31 December 24154154
Net book value
At 31 December 24446446
At 31 December 23506506
4.Tangible fixed assets

Plant & machinery

Fixtures & fittings

Office Equipment

Total

££££
Cost or valuation
At 01 January 2467,76375,2373,493146,493
Additions1,686-6292,315
Disposals-(7,448)-(7,448)
At 31 December 2469,44967,7894,122141,360
Depreciation and impairment
At 01 January 2419,83422,73443743,005
Charge for year14,796--14,796
On disposals-(7,507)-(7,507)
At 31 December 2434,63015,22743750,294
Net book value
At 31 December 2434,81952,5623,68591,066
At 31 December 2347,92952,5033,056103,488
5.Stocks

2024

2023

££
Finished goods188,213149,368
Total188,213149,368
6.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables65,5364,275
Bank borrowings and overdrafts-13,081
Amounts owed to related parties53,715-
Taxation and social security58,76833,744
Other creditors1,3413,342
Accrued liabilities and deferred income18,84728,036
Total198,20782,478
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.